Immunic, Inc.
DE ˙ DB
16,63 € ↓ -16,55 (-49,87%)
2019-04-18
DEL PRIS
SecurityDE:10V / Immunic, Inc.
InstitutionMillennium Management Llc
ManagerIsrael Englander
Latest Disclosed Ownership3,779,922 shares
Latest Disclosed Value $ 4,195,713
Millennium Management Llc ownership in 10V / Immunic, Inc.

On May 15, 2026 - Millennium Management Llc filed a 13F-HR form disclosing ownership of 3,779,922 shares of Immunic, Inc. (DE:10V) valued at $4,195,713 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 3,419,299 shares of Immunic, Inc.. This represents a change in shares of 10.55% during the quarter. The current value of the position is $62,867,663 USD.

Millennium Management Llc has a history of taking positions in derivatives of the underlying security (10V) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:10V / Immunic, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F IMMUNIC COM 4525EP101 3,779,922 360,623 10.55 4,196 129.99 0.0017
2026-02-17 2025-12-31 13F IMMUNIC COM 4525EP101 3,419,299 2,888,829 544.58 1,825 290.58 0.0008
2025-11-14 2025-09-30 13F IMMUNIC COM 4525EP101 530,470 427,361 414.47 468 557.75 0.0002
2025-08-14 2025-06-30 13F IMMUNIC COM 4525EP101 103,109 2,193 2.17 72 -34.86 0.0000
2025-05-15 2025-03-31 13F IMMUNIC COM 4525EP101 100,916 -478,767 -82.59 110 -81.17 0.0001
2025-02-14 2024-12-31 13F IMMUNIC COM 4525EP101 579,683 479,846 480.63 580 253.05 0.0003
2024-11-14 2024-09-30 13F IMMUNIC COM 4525EP101 99,837 70,163 236.45 165 412.50 0.0001
2024-08-14 2024-06-30 13F IMMUNIC COM 4525EP101 29,674 -90,380 -75.28 33 -79.75 0.0000
2024-05-15 2024-03-31 13F IMMUNIC COM 4525EP101 120,054 120,054 158 0.0001
2024-02-14 2023-12-31 13F IMMUNIC COM 4525EP101 0 -106,215 -100.00 0 -100.00
2023-11-14 2023-09-30 13F IMMUNIC COM 4525EP101 106,215 -839,582 -88.77 156 -93.43 0.0001
2023-08-14 2023-06-30 13F IMMUNIC COM 4525EP101 945,797 -318,826 -25.21 2,374 25.96 0.0012
2023-05-15 2023-03-31 13F IMMUNIC COM 4525EP101 1,264,623 533,079 72.87 1,884 83.98 0.0011
2023-02-14 2022-12-31 13F IMMUNIC COM 4525EP101 731,544 -476,950 -39.47 1,024 -73.19 0.0006
2022-11-14 2022-09-30 13F IMMUNIC COM 4525EP101 1,208,494 69,340 6.09 3,819 -3.39 0.0023
2022-08-15 2022-06-30 13F IMMUNIC COM 4525EP101 1,139,154 614,591 117.16 3,953 -33.32 0.0025
2022-05-16 2022-03-31 13F IMMUNIC COM 4525EP101 524,563 -46,138 -8.08 5,928 8.53 0.0031
2022-02-14 2021-12-31 13F IMMUNIC COM 4525EP101 570,701 75,530 15.25 5,462 24.65 0.0028
2021-11-15 2021-09-30 13F IMMUNIC COM 4525EP101 495,171 255,615 106.70 4,382 49.20 0.0026
2021-08-16 2021-06-30 13F IMMUNIC COM 4525EP101 239,556 80,233 50.36 2,937 15.63 0.0018
2021-05-17 2021-03-31 13F IMMUNIC COM 4525EP101 159,323 -53,594 -25.17 2,540 -21.99 0.0018
2021-02-16 2020-12-31 13F IMMUNIC COM 4525EP101 212,917 -119,696 -35.99 3,256 -47.29 0.0024
2020-11-16 2020-09-30 13F IMMUNIC COM 4525EP101 332,613 332,613 6,177 0.0076
2020-08-14 2020-06-30 13F IMMUNIC COM 4525EP101 0 -10,259 -100.00 0 -100.00
2020-05-14 2020-03-31 13F IMMUNIC COM 4525EP101 10,259 -1,204 -10.50 61 -45.05 0.0001
2020-02-14 2019-12-31 13F IMMUNIC COM 4525EP101 11,463 -474 -3.97 111 -7.50 0.0001
2019-11-14 2019-09-30 13F IMMUNIC COM 4525EP101 11,937 -17,872 -59.96 120 -64.91 0.0002
2019-08-15 2019-06-30 13F/A-1 IMMUNIC COM 4525EP101 29,809 29,809 -99.36 342 -99.87 0.0005
2019-08-14 2019-06-30 13F CISCO SYS COM 4525EP101 4,642,473 254,083
2019-02-15 2018-12-31 13F/A-1 VITAL THERAPIES COM 92847R104 0 -794,857 -100.00 0 -100.00
2018-11-14 2018-09-30 13F VITAL THERAPIES COM 92847R104 794,857 784,501 7,575.33 219 208.45 0.0003
2018-08-14 2018-06-30 13F VITAL THERAPIES COM 92847R104 10,356 -404,184 -97.50 71 -97.48 0.0001
2018-05-15 2018-03-31 13F VITAL THERAPIES COM 92847R104 414,540 164,175 65.57 2,819 89.19 0.0038
2018-02-14 2017-12-31 13F VITAL THERAPIES COM 92847R104 250,365 -172,832 -40.84 1,490 -30.28 0.0021
2017-11-14 2017-09-30 13F VITAL THERAPIES COM 92847R104 423,197 -79,974 -15.89 2,137 46.47 0.0033
2017-08-14 2017-06-30 13F VITAL THERAPIES COM 92847R104 503,171 414,036 464.50 1,459 308.68 0.0026
2017-05-15 2017-03-31 13F VITAL THERAPIES COM 92847R104 89,135 -100,028 -52.88 357 -56.62 0.0007
2017-02-14 2016-12-31 13F VITAL THERAPIES COM 92847R104 189,163 189,163 823 0.0017
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2022-11-14 2022-09-30 13F IMMUNIC COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2022-08-15 2022-06-30 13F IMMUNIC COM Call 330,500 88.86 1,147 -42.01 n/a n/a n/a
2022-05-16 2022-03-31 13F IMMUNIC COM Call 175,000 1,978 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.